Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PODO: PF-06730512 in FSGS
NCT03448692Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2018
- Primary completion
- Feb 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of PF-06730512 in focal segmental glomerulosclerosis (FSGS), sponsored by Pfizer. Started Oct 2018; status: terminated.
02
Drugs
PF-06730512
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03448692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448692.